2026年2月11日，美中嘉和集团(02453.HK)在国际化战略布局上迈出里程碑式一步。该集团总裁姜伟与 广州泰和肿瘤医院院长钱朝南携核心团队，与印度尼西亚东爪哇省规模最大的综合性医院——泗水国立 医院(National Hospital)正式签署《关于共建综合肿瘤服务中心的合作备忘录》。 • AI智能"点睛"：打破时空界限，激活本地医疗作为本次合作的"点睛之笔"，美中嘉和自主研发的肿瘤 治疗大模型及AI辅助诊疗系统的落地，标志着合作进入了智能化赋能的新阶段。该系统将首先赋能本 地医生，通过大幅提升诊疗效率与精准度，让临床决策更科学。其更深层的价值在于，它将作为桥梁， 通过数字平台开启"跨越国界的医疗协作"新模式——提供远程会诊、第二诊疗意见及MDT多学科讨 论。在此模式下，美中嘉和的专家团队可与印尼医生实时协同，为复杂病例联合制定最优治疗方案，真 正让优质医疗资源突破地域限制，覆盖更广泛的区域。 二、 生态共建：以全周期关怀，铸就有精度更有温度的医疗服务 技术与模式的价值，最终必须以患者获益为依归。因此，本次合作的核心并非单纯的技术输出，而是围 绕"共建肿瘤治疗中心"这一载体，为印尼乃至东南亚构建一个"有 ...

2026年2月11日，美中嘉和集团(02453.HK)在国际化战略布局上迈出里程碑式一步。该集团总裁姜伟与 广州泰和肿瘤医院院长钱朝南携核心团队，与印度尼西亚东爪哇省规模最大的综合性医院——泗水国立 医院(National Hospital)正式签署《关于共建综合肿瘤服务中心的合作备忘录》。 此次签约，标志着美中嘉和"医疗+AI"的全球化输出正式启航，不仅是公司全球化战略的关键里程碑， 更是中国高端医疗技术自主创新能力与国际影响力的一次关键跨越。双方将携手在印尼泗水打造一个高 水平的肿瘤诊疗服务平台，致力于为当地民众引入国际标准的医疗服务，并以此为契机，为破解东南亚 普遍面临的肿瘤医疗资源短缺难题，提供一个可借鉴的"印尼模板"。 【深度解读：为何此次合作堪称"破局之举"?】 当前，肿瘤已成为威胁东南亚民众健康的重大挑战。然而，区域内高端医疗资源却严重失衡——尖端设 备稀缺、标准化诊疗体系缺失、AI辅助工具不足，迫使无数患者踏上艰辛的跨境求医路。美中嘉和此 次合作，正是直击这一痛点，以系统性方案引领区域医疗标准升级。 一、 双擎驱动：以"中国智慧"破解全球性医疗难题 美中嘉和深耕肿瘤领域多年，此次带来的不仅是单 ...

记者丨宋鹏 崔雯晴 邓志良 贺枫乔 邓晓俊 癌症从来不只是身体里的一个病灶，它是一场关于选择、尊严甚至是希望的全面考验。广州泰 和肿瘤医院院长钱朝南表示，曾有一项数据显示，十年前，一位肿瘤患者平均需拨打超过15个 电话，才能寻求到相对满意的治疗方案。这反映出肿瘤患者面临的首要挑战——信息的不对 称。 当一份肿瘤诊断书突如其来，患者与家庭面临的往往不仅是疾病本身，更是信息迷雾下的抉择 困境、对远期生活质量的忧虑以及先进治疗手段的可及性难题。在精准医学快速发展的今天， 理想的肿瘤治疗图景应是怎样？又如何将这幅图景变为每位患者可触及的现实？ 2025年12月，广州泰和肿瘤医院质子中心运营满一周年。这个华南首套质子治疗装置，在一年 内治疗了来自全球的550位患者，年龄跨度从13个月到91岁。但比技术突破更值得关注的，是 钱朝南和他团队正在推动的一场肿瘤治疗理念的深层变革。 "肿瘤治疗的目标，已从追求五年生存率，进化到追求有质量的长期生存。我们不仅要回答能 否治好，更要回答患者将如何生活。"广州泰和肿瘤医院院长钱朝南近日在接受岭南大医生主 理人宋鹏专访时表示，现代肿瘤治疗的深刻进化，在于其必须同步考量根治疾病与守护患者 ...

孙燕出生于1929年，1956年毕业于北京协和医学院，同年在北京协和医院参加工作，1959年进入中国医学科学院肿瘤医院工作，曾担任内科主任、 新药临床研究中心主任等职。1999年当选中国工程院院士。 孙燕是中国肿瘤内科治疗的创始人和开拓者之一。作为学科开创者，他引领了中国肿瘤内科从无到有的发展。他率先倡导综合治疗理念，在国内率先开 展新药研发与临床转化，并积极探索中西医结合防治路径。他曾获国家科学技术进步奖一等奖、全国卫生健康系统先进工作者、中国医师奖等奖励或荣 誉。 孙燕率先倡导肿瘤综合治疗理念，主持临床试验近80余项，培养肿瘤内科人才千余人。他参与开发包括N-甲酰溶肉瘤素、埃克替尼、榄香烯注射液、 重组人血管内皮抑素等在内的30多种新药，其中，埃克替尼是中国首个具有完全自主知识产权的小分子靶向抗癌药。他开发的贞芪扶正系列产品多年 来畅销国内外，并促进了当地药业的发展，使定西这一"苦甲天下"的地区脱贫，他也因此入选2012年"感动甘肃"的代表。 孙燕逝世后，肿瘤医生、肿瘤行业从业者纷纷在社交媒体发文纪念。 孙燕是中国肿瘤内科治疗的创始人和开拓者之一。孙燕逝世 后，肿瘤医生、肿瘤行业从业者纷纷在社交媒体发文纪 ...

经济观察报 记者 张铃 据中国工程院官网消息，中国工程院院士、中国著名的临床肿瘤专家，中国内科肿瘤学的开拓者和奠基 人孙燕于2026年1月24日逝世，享年97岁。 孙燕逝世后，肿瘤医生、肿瘤行业从业者纷纷在社交媒体发文纪念。 中国临床肿瘤学协作专业委员会（CSCO）在《沉痛哀悼CSCO创始人、荣誉主席孙燕院士》一文中写 道，孙燕亲自发起并着手筹备了CSCO的创立，确立团结、务实、协作的办会宗旨。在他的推动下，学 会积极与ASCO、ESMO等国际权威组织进行深度的交流与合作，协助推动国际多中心临床研究接轨， 促进中国抗肿瘤药物研发事业不断发展，培养了一大批活跃在中国肿瘤学界前沿的领军人才与骨干力 量，实现了承上启下、出成果出人才的夙愿。 "您的一生，是对仁心仁术与大医精诚最完美的诠释。"江西中医药大学附属医院肿瘤科主任李志明写 道，上世纪五十年代，当中国实体瘤研究领域尚处荒芜之际，孙燕临危受命，与周际昌等先驱一道，以 五张病床为起点，开创了中国的肿瘤内科事业。他还提到孙燕牵头组织全国肿瘤死因调查、绘制首部 《恶性肿瘤地图集》、推动学科体系建设等贡献。 河南省肿瘤医院内科主任医师陈小兵撰文回忆听孙燕讲课和请孙燕会 ...

据光明日报全媒体1月26日消息，中国共产党党员，中国工程院院士，我国肿瘤内科学主要奠基人与开 拓者，中国医学科学院肿瘤医院主任医师、教授孙燕同志，因病医治无效，于2026年1月24日在北京逝 世，享年96岁。 公开简历显示，孙燕，男，汉族，河北乐亭人，1929年2月出生。1956年毕业于北京协和医学院，获医 学博士学位，同年在北京协和医院参加工作，1959年进入中国医学科学院肿瘤医院工作，曾担任内科主 任、新药临床研究中心主任等职。1985年11月加入中国共产党。1999年当选中国工程院院士。 孙燕将毕生奉献给了肿瘤防治事业。作为学科开创者，他引领了我国肿瘤内科从无到有的发展。他推动 学科建设，率先倡导综合治疗理念，在国内率先开展新药研发与临床转化，并积极探索中西医结合防治 路径。他主持开发的贞芪扶正系列产品，有力促进了地方药业发展与脱贫事业。曾获国家科学技术进步 奖一等奖、全国卫生健康系统先进工作者、中国医师奖等奖励或荣誉。享受国务院政府特殊津贴。 来源：光明日报 编辑：赵晓倩 责编：王珊珊 ...

Core Viewpoint - The appointment of Jiang Wei as the new president of Meizhong Jiahe Medical Technology Development Group is seen as a significant signal of the company's transition from traditional medical services to an intelligent tumor diagnosis and treatment ecosystem [1][2]. Group 1: Leadership Transition - Jiang Wei, with a strong background in finance and technology, takes over from Fu Xiao, who retired due to age and organizational adjustments [1]. - Jiang Wei has nearly 20 years of experience in investment banking and capital operations, having previously worked at Ernst & Young and China International Capital Corporation (CICC) before joining Meizhong Jiahe in 2020 [1][2]. Group 2: Strategic Focus - The company aims to integrate its diagnostic capabilities and data resources with AI technology, marking a shift where AI becomes a core driver of the group's strategy [2][3]. - Jiang Wei's leadership is expected to enhance diagnostic efficiency and explore the commercial potential of data assets derived from clinical data [3]. Group 3: Industry Context - The healthcare industry is evolving from a focus on expanding physical infrastructure to improving efficiency and algorithms, indicating a competitive shift [4]. - The appointment of a leader with both capital and technical expertise is anticipated to amplify the company's long-standing capabilities in tumor diagnosis through AI and international expansion strategies [4].

Core Viewpoint - The appointment of Jiang Wei as the new CEO of Meizhong Jiahe signals a strategic shift from traditional medical services to an intelligent tumor diagnosis and treatment ecosystem, emphasizing the integration of AI technology into core operations [1][3]. Group 1: Leadership Transition - Jiang Wei, with a strong background in finance and technology, takes over as CEO, indicating a focus on leveraging AI in the healthcare sector [2]. - His previous experience in leading the AI business unit positions him well to drive the company's transformation [2]. Group 2: Strategic Focus on AI - The company aims to integrate AI deeply into its core tumor treatment operations, marking a shift where AI becomes a central driver of strategy rather than a supplementary tool [3]. - The focus will be on enhancing diagnostic capabilities and optimizing clinical pathways through AI [4]. Group 3: Data Asset Utilization - Meizhong Jiahe plans to convert its extensive clinical data into standardized data assets for training more precise AI models, potentially exploring commercial opportunities for data [5]. - The company possesses a unique offline tumor hospital network and vast imaging diagnostic data, which can be leveraged for AI advancements [5]. Group 4: International Expansion - The company is looking to actively expand its overseas business, with standardized medical AI products and high-end tumor treatment services being more conducive to international growth [6]. - Jiang Wei's investment banking background provides a strategic advantage in facilitating technology exports and international capital collaborations [6]. Group 5: Industry Evolution - The healthcare industry is shifting from a focus on acquiring resources to enhancing efficiency and algorithmic capabilities [7]. - Jiang Wei's leadership is expected to amplify the company's long-standing tumor treatment capabilities through AI and international strategies, presenting a new narrative in the capital market [8].

Group 1 - The core viewpoint of the articles highlights the advancements in cancer prevention and control in China, emphasizing the importance of multi-disciplinary collaboration and innovative treatment approaches [1][3] - Experts noted that the five-year survival rates for certain cancers, such as breast and prostate cancer, have reached over 90%, indicating significant progress in cancer treatment [1] - The "People's Good Doctor · Jinshan Camellia Plan" has gained substantial social influence, growing from 30 million to 420 million in impact over five years, showcasing its effectiveness in promoting cancer prevention [3] Group 2 - The plan has established a database of over 130,000 professionals engaged in cancer diagnosis and treatment, enhancing the professional influence in the field [3] - There is an ongoing exploration of AI applications in cancer-related clinical research and public education, aiming to leverage digital technology for better cancer prevention [3] - Young and mid-career doctors are encouraged to participate in clinical research and innovation, with aspirations to learn from international medical advancements [3]

Core Insights - The "People's Good Doctor Jinshan Camellia Plan" conference highlighted advancements in cancer prevention and control, focusing on high-quality development in the field [1] Group 1: Cancer Treatment Advances - Hepatobiliary tumor treatment has entered an immune-dominant phase, significantly extending patient survival and creating curative opportunities for inoperable tumors [1] - Lung cancer patients have seen improved survival rates due to the promotion of precision diagnosis and treatment, with breakthroughs in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) [2] - Innovative drugs and treatment strategies in esophageal and gastric cancers have led to significant clinical advancements, although challenges in standardization and precision screening remain [2] Group 2: Multidisciplinary Collaboration - A multidisciplinary collaboration model is becoming mainstream in cancer treatment, allowing for personalized treatment plans through joint consultations among various specialists [4] - There is a need for improved management of patient follow-ups and a more balanced regional development in cancer prevention and treatment [4] Group 3: Emerging Treatment Modalities - Immunotherapy combined with chemotherapy has become a first-line treatment for advanced nasopharyngeal carcinoma, with ongoing exploration of different intervention models [3] - The application of CAR-T cell therapy and targeted drugs has provided long-term survival opportunities for previously hard-to-treat hematological cancer patients [3] Group 4: Future Directions - Continuous innovation in clinical research and acceleration of new treatment technologies are essential for enhancing cancer prevention and treatment systems [5] - The focus should be on early screening, diagnosis, and treatment management to provide patients with better survival prospects [5]